Hepatitis Monthly

Published by: Kowsar

Development of a Chemiluminescence Immunoassay for Serum YB-1 and its Clinical Application as a Potential Diagnostic Marker for Hepatocellular Carcinoma

Li Pu 1 , Shi Jing 2 , Guo Bianqin 1 , Liu Ping 1 , Liang Qindong 1 , Liu Chenggui 1 , Cheng Feng 1 , Kuang Wenbin 1 , Wang Qin 1 , Dong Jinyu 1 , Xia Qianfeng 3 , Liu Yu 4 and Tu Zhiguang 1 , *
Authors Information
1 Key Laboratory of Clinical Laboratory Diagnostics, College of Laboratory Medicine, Chongqing Medical University, Chongqing, China
2 Department of Clinical Laboratory, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China
3 Department of Laboratory Medicine, Hainan Medical College, Hainan, China
4 Department of Clinical Laboratory, Chongqing Tumor Hospital, Chongqing, China
Article information
  • Hepatitis Monthly: July 01, 2013, 13 (7); e8918
  • Published Online: July 3, 2013
  • Article Type: Research Article
  • Received: November 1, 2012
  • Revised: January 14, 2013
  • Accepted: January 24, 2013
  • DOI: 10.5812/hepatmon.8918

To Cite: Pu L, Jing S, Bianqin G, Ping L, Qindong L, et al. Development of a Chemiluminescence Immunoassay for Serum YB-1 and its Clinical Application as a Potential Diagnostic Marker for Hepatocellular Carcinoma, Hepat Mon. 2013 ; 13(7):e8918. doi: 10.5812/hepatmon.8918.

Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Diamandis EP, Hoffman BR, Sturgeon CM. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the Use of Tumor Markers. Clin Chem. 2008; 54(11): 1935-9[DOI][PubMed]
  • 2. Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012; 39(4): 410-33[DOI][PubMed]
  • 3. Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012; 13(8): 817-26[DOI][PubMed]
  • 4. Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays. 2003; 25(7): 691-8[DOI][PubMed]
  • 5. En-Nia A, Yilmaz E, Klinge U, Lovett DH, Stefanidis I, Mertens PR. Transcription factor YB-1 mediates DNA polymerase alpha gene expression. J Biol Chem. 2005; 280(9): 7702-11[DOI][PubMed]
  • 6. Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E, et al. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res. 2006; 66(9): 4872-9[DOI][PubMed]
  • 7. Tay WL, Yip GW, Tan PH, Matsumoto K, Yeo R, Ng TP, et al. Y-Box-binding protein-1 is a promising predictive marker of radioresistance and chemoradioresistance in nasopharyngeal cancer. Mod Pathol. 2009; 22(2): 282-90[DOI][PubMed]
  • 8. Wachowiak R, Thieltges S, Rawnaq T, Kaifi JT, Fiegel H, Metzger R, et al. Y-box-binding protein-1 is a potential novel tumour marker for neuroblastoma. Anticancer Res. 2010; 30(4): 1239-42[PubMed]
  • 9. Kuwano M, Oda Y, Izumi H, Yang SJ, Uchiumi T, Iwamoto Y, et al. The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther. 2004; 3(11): 1485-92[PubMed]
  • 10. Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med. 1997; 3(4): 447-50[PubMed]
  • 11. Dhillon J, Astanehe A, Lee C, Fotovati A, Hu K, Dunn SE. The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells. Oncogene. 2010; 29(47): 6294-300[DOI][PubMed]
  • 12. Janz M, Harbeck N, Dettmar P, Berger U, Schmidt A, Jurchott K, et al. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer. 2002; 97(3): 278-82[PubMed]
  • 13. Shibahara K, Sugio K, Osaki T, Uchiumi T, Maehara Y, Kohno K, et al. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res. 2001; 7(10): 3151-5[PubMed]
  • 14. Das S, Chattopadhyay R, Bhakat KK, Boldogh I, Kohno K, Prasad R, et al. Stimulation of NEIL2-mediated oxidized base excision repair via YB-1 interaction during oxidative stress. J Biol Chem. 2007; 282(39): 28474-84[DOI][PubMed]
  • 15. Shiota M, Zoubeidi A, Kumano M, Beraldi E, Naito S, Nelson CC, et al. Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer. Mol Cancer Res. 2011; 9(12): 1755-66[DOI][PubMed]
  • 16. Szczuraszek K, Halon A, Materna V, Mazur G, Wrobel T, Kuliczkowski K, et al. Elevated YB-1 expression is a new unfavorable prognostic factor in non-Hodgkin's lymphomas. Anticancer Res. 2011; 31(9): 2963-70[PubMed]
  • 17. Frye BC, Halfter S, Djudjaj S, Muehlenberg P, Weber S, Raffetseder U, et al. Y-box protein-1 is actively secreted through a non-classical pathway and acts as an extracellular mitogen. EMBO Rep. 2009; 10(7): 783-9[DOI][PubMed]
  • 18. Tacke F, Kanig N, En-Nia A, Kaehne T, Eberhardt CS, Shpacovitch V, et al. Y-box protein-1/p18 fragment identifies malignancies in patients with chronic liver disease. BMC Cancer. 2011; 11: 185[DOI][PubMed]
  • 19. Kuwano M, Uchiumi T, Hayakawa H, Ono M, Wada M, Izumi H, et al. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Sci. 2003; 94(1): 9-14[PubMed]
  • 20. Graslund S, Nordlund P, Weigelt J, Hallberg BM, Bray J, Gileadi O, et al. Protein production and purification. Nat Methods. 2008; 5(2): 135-46[DOI][PubMed]
  • 21. Norwood TH, Zeigler CJ, Martin GM. Dimethyl sulfoxide enhances polyethylene glycol-mediated somatic cell fusion. Somatic Cell Genet. 1976; 2(3): 263-70[PubMed]
  • 22. Powers DM. Interference Testing in Clinical Chemistry: Approved Guideline. 2002;
  • 23. Tholen DW. Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach, Approved Guideline. 2003;
  • 24. Tholen DW. Evaluation of Precision Performance of Quantitative Measurement Methods: Approved Guideline. 2004;
  • 25. Raffetseder U, Rauen T, Boor P, Ostendorf T, Hanssen L, Floege J, et al. Extracellular YB-1 blockade in experimental nephritis upregulates Notch-3 receptor expression and signaling. Nephron Exp Nephrol. 2011; 118(4)-8[DOI][PubMed]
  • 26. Rauen T, Raffetseder U, Frye BC, Djudjaj S, Muhlenberg PJ, Eitner F, et al. YB-1 acts as a ligand for Notch-3 receptors and modulates receptor activation. J Biol Chem. 2009; 284(39): 26928-40[DOI][PubMed]
  • 27. Giovannini C, Gramantieri L, Chieco P, Minguzzi M, Lago F, Pianetti S, et al. Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism. J Hepatol. 2009; 50(5): 969-79[DOI][PubMed]
  • 28. Giovannini C, Lacchini M, Gramantieri L, Chieco P, Bolondi L. Notch3 intracellular domain accumulates in HepG2 cell line. Anticancer Res. 2006; 26(3A): 2123-7[PubMed]
  • 29. Haruki N, Kawaguchi KS, Eichenberger S, Massion PP, Olson S, Gonzalez A, et al. Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers. Cancer Res. 2005; 65(9): 3555-61[DOI][PubMed]
  • 30. Konishi J, Kawaguchi KS, Vo H, Haruki N, Gonzalez A, Carbone DP, et al. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res. 2007; 67(17): 8051-7[DOI][PubMed]
  • 31. Serafin V, Persano L, Moserle L, Esposito G, Ghisi M, Curtarello M, et al. Notch3 signalling promotes tumour growth in colorectal cancer. J Pathol. 2011; 224(4): 448-60[DOI][PubMed]
  • 32. Bergmann S, Royer-Pokora B, Fietze E, Jurchott K, Hildebrandt B, Trost D, et al. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res. 2005; 65(10): 4078-87[DOI][PubMed]
  • 33. Gimenez-Bonafe P, Fedoruk MN, Whitmore TG, Akbari M, Ralph JL, Ettinger S, et al. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate. 2004; 59(3): 337-49[DOI][PubMed]
  • 34. Huang X, Ushijima K, Komai K, Takemoto Y, Motoshima S, Kamura T, et al. Co-expression of Y box-binding protein-1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer. Gynecol Oncol. 2004; 93(2): 287-91[DOI][PubMed]
  • 35. Oda Y, Sakamoto A, Shinohara N, Ohga T, Uchiumi T, Kohno K, et al. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin Cancer Res. 1998; 4(9): 2273-7[PubMed]
  • 36. Saji H, Toi M, Saji S, Koike M, Kohno K, Kuwano M. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma. Cancer Lett. 2003; 190(2): 191-7[PubMed]
  • 37. Yang JY, Ha SA, Yang YS, Kim JW. p-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistance. BMC Cancer. 2010; 10: 388[DOI][PubMed]
  • 38. Yasen M, Kajino K, Kano S, Tobita H, Yamamoto J, Uchiumi T, et al. The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma. Clin Cancer Res. 2005; 11(20): 7354-61[DOI][PubMed]
  • 39. Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, et al. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res. 2008; 10(5)[DOI][PubMed]
  • 40. Huang J, Tan PH, Li KB, Matsumoto K, Tsujimoto M, Bay BH. Y-box binding protein, YB-1, as a marker of tumor aggressiveness and response to adjuvant chemotherapy in breast cancer. Int J Oncol. 2005; 26(3): 607-13[PubMed]
  • 41. Jurchott K, Kuban RJ, Krech T, Bluthgen N, Stein U, Walther W, et al. Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells. PLoS Genet. 2010; 6(12)[DOI][PubMed]
  • 42. To K, Zhao Y, Jiang H, Hu K, Wang M, Wu J, et al. The phosphoinositide-dependent kinase-1 inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-ace tamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor. Mol Pharmacol. 2007; 72(3): 641-52[DOI][PubMed]
  • 43. Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst. 1993; 85(8): 632-9[PubMed]
  • 44. Gluz O, Mengele K, Schmitt M, Kates R, Diallo-Danebrock R, Neff F, et al. Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. J Clin Oncol. 2009; 27(36): 6144-51[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments